據(jù)香港《文匯報》報道,，最新一期《科學(xué)》（Science）雜志報道,，美國科研人員發(fā)現(xiàn)兩種強力抗體,，名為“VRCO1”和“VRCO2”,，能夠中和逾90%已知的艾滋病病毒（HIV）毒株（strain）,，防止病毒株感染人類細胞,。這項新發(fā)現(xiàn)為改良HIV病毒疫苗設(shè)計和其它疾病的抗體治療，帶來突破性發(fā)展,。
報告稱,，美國國家衛(wèi)生研究院（NIH）在華裔科學(xué)家鄺廣杰（Peter Kwong）帶領(lǐng)下，從HIV感染者的血里,，發(fā)現(xiàn)“VRCO1”和“VRCO2”這兩種天然抗體,。
NIH旗下的國家過敏與感染疾病研究中心（NIAID）主任福西博士表示，科研人員發(fā)現(xiàn)這兩種對HIV具有異常廣泛中和能力的抗體,，并對抗體如何發(fā)揮效能進行結(jié)構(gòu)性分析,，有助研究對抗HIV疫苗。
福西博士又指,，專家小組利用自行研發(fā)的分子組件,，發(fā)現(xiàn)這兩種新抗體，新技術(shù)或能應(yīng)用于其它傳染疾病的疫苗設(shè)計,。(生物谷Bioon.net)
更多閱讀
PNAS：HIV預(yù)治療可能減少耐藥株的數(shù)量
PNAS：發(fā)現(xiàn)識別T細胞抑制HIV的機制
ACS Chem. Biol：預(yù)防HIV傳播的新分子合成
Nat. Biotech.：艾滋病基因治療新進展
Nat. Biotech.：艾滋病基因治療新進展
生物谷推薦原文出處：
Science DOI: 10.1126/science.1192819
Structural Basis for Broad and Potent Neutralization of HIV-1 by Antibody VRC01
Tongqing Zhou,1 Ivelin Georgiev,1,* Xueling Wu,1,* Zhi-Yong Yang,1,* Kaifan Dai,1 Andrés Finzi,2 Young Do Kwon,1 Johannes Scheid,3 Wei Shi,1 Ling Xu,1 Yongping Yang,1 Jiang Zhu,1 Michel C. Nussenzweig,3 Joseph Sodroski,2,4 Lawrence Shapiro,1,5 Gary J. Nabel,1 John R. Mascola,1 Peter D. Kwong1,
During HIV-1 infection, antibodies are generated against the region of the viral gp120 envelope glycoprotein that binds CD4, the primary receptor for HIV-1. Among these antibodies, VRC01 achieves broad neutralization of diverse viral strains. Here, we determine the crystal structure of VRC01 in complex with an HIV-1 gp120 core. VRC01 partially mimics CD4 interaction with gp120. A shift from the CD4-defined orientation, however, focuses VRC01 onto the vulnerable site of initial CD4 attachment, allowing it to overcome the glycan and conformational masking that diminishes the neutralization potency of most CD4-binding-site antibodies. To achieve this recognition, VRC01 contacts gp120 mainly through V-gene–derived regions substantially altered from their genomic precursors. Partial receptor mimicry and extensive affinity maturation thus facilitate neutralization of HIV-1 by natural human antibodies.
1 Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20892, USA.
2 Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Department of Pathology, Division of AIDS, Harvard Medical School, Boston, MA 02115, USA.
3 Laboratory of Molecular Immunology and Howard Hughes Medical Institute, The Rockefeller University, New York, NY 10065, USA.
4 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, MA 02115, USA.
5 Department of Biochemistry and Molecular Biophysics, Columbia University, New York, NY 10032, USA.
